LYEL Stock Price, Lyell Immunopharma, Inc. Quote, Chart

Market Summary

USD2.33+0.10

Delayedas of 22 Apr 2024, 11:58 am

4.48%

LYEL Stock Price

View Fullscreen

LYEL RSI Chart

LYEL Valuation

Market Cap

566.6M

Price/Earnings (Trailing)

-2.41

Price/Sales (Trailing)

4.4K

Price/Free Cashflow

-3.41

LYEL Price/Sales (Trailing)

LYEL Profitability

Return on Equity

-35.82%

Return on Assets

-31.28%

Free Cashflow Yield

-29.36%

LYEL Fundamentals

LYEL Revenue

Revenue (TTM)

130.0K

Rev. Growth (Yr)

-99.97%

Rev. Growth (Qtr)

-48%

LYEL Earnings

Earnings (TTM)

-234.6M

Earnings Growth (Yr)

-530.34%

Earnings Growth (Qtr)

-4.08%

Breaking Down LYEL Revenue

52 Week Range

1.333.97

(Low)(High)

Last 7 days

-25.6%

Last 30 days

9.8%

Last 90 days

17.9%

LYEL Financial Health

Current Ratio

16.07

LYEL Investor Care

Shares Dilution (1Y)

1.02%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	63.5M	42.4M	21.3M	130.0K
2022	29.2M	47.7M	66.2M	84.7M
2021	8.9M	8.5M	10.0M	10.7M
2020	0	3.0M	5.4M	7.8M
2019	0	0	0	657.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lyell Immunopharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2024	lee gary k.	acquired	-	-	40,000	chief scientific officer
Feb 09, 2024	newton charles w.	acquired	-	-	40,000	chief financial officer
Feb 09, 2024	hill stephen j.	acquired	-	-	40,000	chief operating officer
Feb 09, 2024	lang matthew	acquired	-	-	50,000	chief business officer
Feb 09, 2024	seely lynn	acquired	-	-	200,000	president and ceo
Aug 15, 2023	klausner richard	sold	-132,286	2.28	-58,020	-
Sep 23, 2022	klausner richard	sold	-71,041	6.4001	-11,100	-
Sep 08, 2022	bishop hans edgar	acquired	14,538	0.1	145,380	-
Feb 23, 2022	bishop hans edgar	acquired	99,342	0.1	993,428	-
Dec 14, 2021	friedman cathy	acquired	-	-	218,722	-

Which funds bought or sold LYEL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	-	-%
Apr 17, 2024	Clarius Group, LLC	unchanged	-	115,759	890,145	0.06%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	55.42	126,579	287,514	0.01%
Apr 05, 2024	CWM, LLC	added	8.57	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-19.55	1,534,520	26,391,800	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	133	1,645,160	2,435,460	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	40,030	167,342	-%
Feb 26, 2024	Virtu Financial LLC	new	-	29,000	29,000	-%
Feb 16, 2024	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	sold off	-100	-40,000	-	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-51,000	-	-%

Are Funds Buying or Selling LYEL?

Are funds buying LYEL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LYEL

No. of Funds

Unveiling Lyell Immunopharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	arch venture fund ix, l.p.	14.5%	36,412,716	SC 13G/A
Feb 13, 2024	vanguard group inc	5.40%	13,604,027	SC 13G/A
Jan 29, 2024	blackrock inc.	5.7%	14,302,220	SC 13G
Feb 13, 2023	foresite capital fund iv, l.p.	4.0%	1e+07	SC 13G/A
Feb 09, 2023	vanguard group inc	5.05%	12,591,230	SC 13G
Feb 14, 2022	mwg management ltd.	8.38%	20,162,332	SC 13G
Feb 14, 2022	newton (ptc) ltd	6.28%	15,093,969	SC 13G
Feb 14, 2022	arch venture fund ix, l.p.	15.1%	36,412,716	SC 13G
Feb 11, 2022	foresite capital fund iv, l.p.	5.5%	13,282,181	SC 13G

Recent SEC filings of Lyell Immunopharma, Inc.

View All Filings

Date Filed	Form Type	Document
Feb 29, 2024	S-8	Employee Benefits Plan
Feb 29, 2024	S-3	S-3
Feb 28, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	4	Insider Trading
Feb 13, 2024	4	Insider Trading
Feb 13, 2024	4	Insider Trading
Feb 13, 2024	4	Insider Trading

Peers (Alternatives to Lyell Immunopharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Lyell Immunopharma, Inc. News

Latest updates

Lyell Immunopharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Revenue	-48.0%	0.00	0.00	0.00	24.00	48.00	0.00	36.00	19.00	3.00	3.00	3.00	2.00	2.00	1.00	3.00	-
Operating Expenses	0.8%	60.00	59.00	66.00	63.00	63.00	66.00	73.00	69.00	50.00	52.00	65.00	58.00	42.00	38.00	106	-
S&GA Expenses	-15.1%	13.00	16.00	19.00	19.00	26.00	26.00	30.00	34.00	32.00	21.00	19.00	17.00	15.00	14.00	10.00	-
R&D Expenses	7.2%	47.00	44.00	47.00	45.00	38.00	42.00	44.00	36.00	19.00	31.00	46.00	42.00	35.00	25.00	97.00	-
Net Income	-4.1%	-52.93	-50.85	-63.89	-66.96	-8.40	-70.25	-36.32	-68.14	-83.71	-48.87	-62.59	-55.04	-38.86	-35.72	-100	-
Net Income Margin	-20092.8%	0.00	-8.94*	-4.94*	-2.86*	-2.16*	-3.91*	-4.97*	-9.03*	-23.48*	-20.49*	-22.73*	-25.74*	-26.36*	-21.63*	-30.76*	-
Free Cashflow	-7.3%	-40.66	-37.88	-40.09	-47.74	-44.85	-39.89	-51.50	-57.58	-43.48	-37.09	-58.39	-52.79	-51.61	-34.27	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-5.7%	750	795	835	880	938	977	1,022	1,072	1,127	1,198	1,230	908
Current Assets	-5.5%	555	587	606	624	651	660	667	626	626	631	835	618
Cash Equivalents	-49.1%	146	286	224	109	124	116	206	223	294	394	564	141
Net PPE	-5.0%	103	108	114	119	123	126	128	126	120	116	110	77.00
Liabilities	-2.4%	95.00	97.00	98.00	97.00	104	157	154	191	198	212	208	190
Current Liabilities	-1.6%	35.00	35.00	34.00	31.00	37.00	51.00	50.00	41.00	47.00	59.00	64.00	49.00
Shareholder's Equity	-6.1%	655	698	737	784	833	820	868	881	930	986	1,022	-292
Retained Earnings	-5.6%	-1,002	-949	-898	-834	-767	-759	-688	-652	-584	-500	-451	-334
Additional Paid-In Capital	0.6%	1,657	1,648	1,638	1,622	1,608	1,589	1,565	1,540	1,516	1,487	1,474	41.00
Shares Outstanding	0.8%	254	252	251	250	250	248	246	244	136	101	43.00	13.00
Float	-	-	-	654	-	-	-	1,100	-	-	-	2,741	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-7.8%	-40.63	-37.69	-39.16	-46.21	-40.27	-37.10	-44.33	-47.85	-33.21	-25.49	-33.95	-33.60	-26.73	-21.63	-	-
Share Based Compensation	-19.5%	8.00	11.00	14.00	14.00	18.00	19.00	22.00	22.00	21.00	13.00	15.00	13.00	13.00	10.00	-	-
Cashflow From Investing	-201.0%	-100	100	153	32.00	47.00	-57.08	25.00	-26.12	-73.86	-144	-39.47	137	32.00	-89.94	-	-
Cashflow From Financing	630.8%	1.00	-0.14	1.00	-0.07	1.00	5.00	2.00	3.00	7.00	-0.53	393	1.00	0.00	0.00	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

LYEL Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Statement of Comprehensive Income [Abstract]

Revenues

^[1]

$ 130

$ 84,683

$ 10,650

Operating expenses:

Research and development

182,945

159,188

138,693

General and administrative

66,983

117,307

89,057

Other operating income, net

(2,790)

(4,754)

(2,324)

Total operating expenses

247,138

271,741

225,426

Loss from operations

(247,008)

(187,058)

(214,776)

Interest income, net

23,453

7,053

1,165

Other income (expense), net

1,846

1,887

(161)

Impairment of other investments

(12,923)

(5,000)

(36,447)

Total other income (loss), net

12,376

3,940

(35,443)

Net loss

(234,632)

(183,118)

(250,219)

Other comprehensive loss:

Net unrealized gain (loss) on marketable securities

7,505

(5,976)

(1,879)

Comprehensive loss

$ (227,127)

$ (189,094)

$ (252,098)

Net loss per common share, basic (in dollars per share)

$ (0.93)

$ (0.74)

$ (1.84)

Net loss per common share, diluted (in dollars per share)

$ (0.93)

$ (0.74)

$ (1.84)

Weighted-average shares used to compute net loss per common share, basic (in shares)

250,983

247,080

135,918

Weighted-average shares used to compute net loss per common share, diluted (in shares)

250,983

247,080

135,918

[1]	Includes related-party revenue of zero, $84,653 and $10,509 for the years ended December 31, 2023, 2022 and 2021, respectively.

LYEL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 145,647	$ 123,554
Marketable securities	400,576	516,598
Prepaid expenses and other current assets	8,463	11,143
Total current assets	554,686	651,295
Restricted cash	284	280
Marketable securities, non-current	16,506	70,117
Other investments	32,001	44,924
Property and equipment, net	102,654	123,023
Operating lease right-of-use assets	39,663	43,242
Other non-current assets	4,235	4,680
Total assets	750,029	937,561
Current liabilities:
Accounts payable	4,817	3,917
Accrued liabilities and other current liabilities	28,126	28,755
Success payment liabilities	1,576	4,356
Total current liabilities	34,519	37,028
Operating lease liabilities, non-current	56,894	63,168
Other non-current liabilities	3,664	4,113
Total liabilities	95,077	104,309
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized at December 31, 2023 and 2022, respectively; no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 500,000 shares authorized at December 31, 2023 and 2022, respectively; 253,958 and 249,567 shares issued and outstanding at December 31, 2023 and 2022, respectively	25	25
Additional paid-in capital	1,657,133	1,608,306
Accumulated other comprehensive loss	(94)	(7,599)
Accumulated deficit	(1,002,112)	(767,480)
Total stockholders’ equity	654,952	833,252
Total liabilities and stockholders’ equity	$ 750,029	$ 937,561
Common stock authorized (in shares)	500,000,000	500,000,000
Preferred stock authorized (in shares)	10,000,000	10,000,000

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

CEO	Dr. Lynn Seely M.D., Ph.D.
WEBSITE	lyell.com
INDUSTRY	Biotechnology
EMPLOYEES	274

Lyell Immunopharma, Inc. Frequently Asked Questions

What is the ticker symbol for Lyell Immunopharma, Inc.? What does LYEL stand for in stocks?

LYEL is the stock ticker symbol of Lyell Immunopharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lyell Immunopharma, Inc. (LYEL)?

As of Fri Apr 19 2024, market cap of Lyell Immunopharma, Inc. is 566.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LYEL stock?

You can check LYEL's fair value in chart for subscribers.

What is the fair value of LYEL stock?

You can check LYEL's fair value in chart for subscribers. The fair value of Lyell Immunopharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lyell Immunopharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LYEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lyell Immunopharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether LYEL is over valued or under valued. Whether Lyell Immunopharma, Inc. is cheap or expensive depends on the assumptions which impact Lyell Immunopharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LYEL.

What is Lyell Immunopharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, LYEL's PE ratio (Price to Earnings) is -2.41 and Price to Sales (PS) ratio is 4.36 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LYEL PE ratio will change depending on the future growth rate expectations of investors.